More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.89B
EPS
-5.9
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.059309
Previous close
$26.97
Today's open
$27
Day's range
$25.82 - $27
52 week range
$25.82 - $56.05
show more
CEO
Marshall Fordyce
Employees
361
Headquarters
Brisbane, CA
Exchange
NASDAQ Global Market
Shares outstanding
72298770
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Vera Therapeutics Q3 Earnings Call Highlights
Vera Therapeutics NASDAQ: VERA reported $10.3 million in third-quarter TRUTAKNA sales, its first partial quarter of commercial revenue, as the company pursues full U.S. approval for the kidney disease treatment.
MarketBeat • Nov 6, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 14,900 shares of Class A common stock and restricted stock units (RSUs) underlying 7,450 shares of Class A common stock to three (3) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
GlobeNewsWire • Nov 6, 2026

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3. ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years; data was presented as a late-breaking oral presentation at the opening plenary session at ASN Kidney Week 2026 with a simultaneous publication in The New England Journal of Medicine.
GlobeNewsWire • Nov 5, 2026

Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
Vera Therapeutics, Inc. (VERA) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to a loss of $1.26 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, which is taking place in Boston, MA from November 9-11, 2026.
GlobeNewsWire • Nov 2, 2026

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
Vera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology's Kidney Week meeting in Denver, alongside publication in The New England Journal of Medicine.
MarketBeat • Oct 23, 2026

Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Seeking Alpha • Oct 22, 2026

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events. Favorable safety profile, and generally comparable to placebo.
GlobeNewsWire • Oct 22, 2026

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026 Q3 2026 financial results investor webcast scheduled at 4:30 p.m.
GlobeNewsWire • Oct 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Vera Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.